To further investigate pharmacological TIAM1/RAC1 signaling inhibition in the context of human BPH, we exposed BPH PDOs with varying concentrations of NSC23766 and assessed growth effects compared with vehicle controls. Here, TIAM1 is linked to benign prostatic hyperplasia.